Abstract
A new series of α-pyridinyl-substituted indeno[2,1-c ]quinoline derivatives was
prepared with good yields according to a two-step synthesis. The
first and key step involves the formation of the ring via three-component
imino Diels-Alder cycloaddition between an aniline, pyridine-2-carbaldehyde,
and indene using boron trifluoride-diethyl ether complex
as a catalyst to produce the corresponding 5,6,6a,11b-tetrahydroindeno[2,1-c ]quinolines. The second step
consisted of their oxidation with powdered sulfur to obtain the
corresponding indeno[2,1-c ]quinolines,
analogues of DNA topoisomerase inhibitor TAS-103.
Key words
cycloaddition - multicomponent reaction - imino
Diels-Alder reaction - indeno[2,1-c ]quinolines
References
1a Kouznetsov V.
Palma A.
Ewert C.
Varlamov A.
J. Heterocycl.
Chem.
1998,
35:
761
1b Katritzky AR.
Rachwal S.
Rachwal B.
Tetrahedron
1996,
52:
15031
1c Carling RW.
Leeson PD.
Moseley AM.
Baker R.
Forster AC.
Grimwood S.
Kemp JA.
Marshall GR.
J.
Med. Chem.
1992,
35:
1942
1d Cai SX.
Zhou Z.-L.
Huang J.-C.
Whittermore ER.
Egbuwoku ZO.
Lü Y.
Hawkinson JE.
Woodward RM.
Keana JFW.
J. Med. Chem.
1996,
39:
3248
2a Bendale P.
Olepu S.
Kumar SP.
Buldule V.
Rivas K.
Nallan L.
Smart B.
Yokoyama K.
Ankala S.
Rao PP.
Floyd D.
Lombardo L.
Williams DK.
Buckner FS.
Chakrabarti D.
Verlinde CMJ.
Van Voorhis WC.
Gelb MH.
J. Med. Chem.
2007,
50:
4585
2b Jacquemond-Collet I.
Benoit-Vical F.
Valentin A.
Stanislas E.
Mallie M.
Fouraste I.
Planta
Med.
2002,
68:
68
3a Nishiyama TT.
Hashiguchi YY.
Sakata ST.
Sakaguchi TT.
Polym. Degrad. Stab.
2003,
79:
225
3b Dorey G.
Lockhart B.
Lestage P.
Casara P.
Bioorg. Med. Chem. Lett.
2000,
10:
9350
4 Calhoun W.
Carlson RP.
Crossley R.
Datko LJ.
Dietrich S.
Heatherington K.
Marshall LA.
Meade PJ.
Opalko A.
Shepherd RG.
J.
Med. Chem.
1995,
38:
1473
5a Gelderblom H.
Sparreboom A. In Drugs Affecting Growth of Tumours
Pinedo HM.
Smorenburg CH.
Birkhauser Verlag;
Switzerland:
2006.
p.83
5b Denny WA.
Baguley BC.
Curr.
Top. Med. Chem.
2003,
3:
339
6a Pommier Y.
Nat. Rev. Cancer
2006,
6:
789
6b Priel E.
Showalter SD.
Roberts M.
Oroszlan S.
Blair DG.
J.
Virol.
1991,
65:
4137
6c Herben VMM.
ten Bokkel HWW.
Schellens JHM.
Beijnen JH.
Pharm. World Sci.
1998,
20:
161
7a Li Q.-Y.
Zu Y.-G.
Shi R.-Z.
Yao L.-P.
Curr.
Med. Chem.
2006,
13:
2021
7b Martínez R.
Chacón-García L.
Curr.
Med. Chem.
2005,
12:
127
7c Liew ST.
Yang LX.
Curr.
Pharm. Des.
2008,
14:
1078
7d Yount G.
Yang Y.
Wong B.
Wang HJ.
Yang LX.
Anticancer
Res.
2007,
27:
3173
8a Denny WA.
Baguley BC.
Curr. Top. Med. Chem.
2003,
3:
339
8b Minderman H.
Wrzosek C.
Cao S.-S.
Utsugi T.
Kobunai T.
Yamada Y.
Rustum YM.
Cancer Chemother.
Pharmacol.
2000,
45:
78
9a Twelves CJ.
Gardner C.
Flavin A.
Sludden J.
Dennis I.
de Bono J.
Beale P.
Vasey P.
Hutchison C.
Macham MA.
Rodríguez A.
Judson I.
Bleehen NM.
Br. J. Cancer
1999,
80:
1786
9b Ohyama T.
Li Y.
Utsugi T.
Irie S.
Yamada Y.
Sato T.
Jpn.
J. Cancer Res.
1999,
44:
691
10a Ewesuedo RB.
Iyer L.
Das S.
Koenig A.
Mani S.
Vogelzang NJ.
Schilsky RL.
Brenckman W.
Ratain MJ.
J. Clin. Oncol.
2001,
19:
2084
10b Ishida K.
Asao T.
Biochim. Biophys. Acta
2002,
1587:
155
10c Osman S.
Luthra SK.
Brady F.
Hume SP.
Brown G.
Harte RJA.
Matthews JC.
Denny WA.
Baguley BC.
Jones T.
Price PM.
Cancer Res.
1997,
57:
2172
10d Dittrich C.
Dieras V.
Kerbrat P.
Punt C.
Sorio R.
Copanigro F.
Paoletti X.
Balincourt C.
Lacombe D.
Fumoleau P.
Invest. New Drugs
2003,
21:
347
11a Anzini M.
Cappelli A.
Vomero S.
J. Heterocycl. Chem.
1991,
28:
1809
11b Cappelli A.
Anzini M.
Vomero S.
Canullo L.
Mennuni L.
Makovec F.
Doucet E.
Hamon M.
Menziani MC.
De Benedetti PG.
Bruni G.
Romeo MR.
Giorgi G.
Donati A.
J. Med. Chem.
1999,
42:
1556
12a Kouznetsov VV.
Romero BAR.
Stashenko EE.
Tetrahedron
Lett.
2007,
48:
8855
12b Sridharan V.
Perumal PT.
Avendaño PC.
Menéndez JC.
Org. Biomol.
Chem.
2007,
5:
1351
12c Akiyama T.
Morita H.
Fuchibe K.
J.
Am. Chem. Soc.
2006,
128:
13070
12d Legros J.
Crousse B.
Qurévitch M.
Bonnet-Delpon D.
Synlett
2006,
1899
12e Akiyama T.
Nakashima S.
Yokota K.
Fuchibe K.
Chem. Lett.
2004,
33:
922
13a Kouznetsov VV.
Tetrahedron
2009,
65:
2721
13b Glushkov VA.
Tolstikov AG.
Russ.
Chem. Rev. (Engl. Transl.)
2008,
77:
137
13c Olsen J.-C.
Oh T.
Tetrahedron
2001,
57:
6099
14 Subba Reddy BV.
Srinivas R.
Yadav JS.
Ramalingam T.
Synth.
Commun.
2001,
31:
1075
15 Babu G.
Perumal PT.
Tetrahedron Lett.
1998,
39:
3225
16 Kobayashi S.
Ishitani H.
Nagayama S.
Synthesis
1995,
1195
17 Yadav JS.
Subba Reddy BV.
Srinivas R.
Madhuri Ch.
Ramalingam T.
Synlett
2001,
240
18 Kobayashi S.
Nagayama S.
J. Am. Chem. Soc.
1996,
118:
8977
19a Kiselyov A.
Smith L.
Armstrong R.
Tetrahedron
1998,
54:
5089
19b Kiselyov A.
Smith L.
Virgilio A.
Armstrong R.
Tetrahedron
1998,
54:
7987
20 Kouznetsov VV.
Ochoa Puentes C.
Zachinno SA.
Gupta M.
Romero BAR.
Sortino M.
Vásquez Y.
Bahsas A.
Amaro-Luis J.
Lett. Org. Chem.
2006,
3:
300
21a Vargas MLY.
Castelli MV.
Kouznetsov VV.
Urbina GJM.
López SN.
Sortino M.
Enriz RD.
Ribas JC.
Zacchino SA.
Bioorg. Med. Chem.
2003,
11:
1531
21b Kouznetsov VV.
Rivero Castro J.
Ochoa Puentes C.
Stashenko EE.
René Martinez J.
Ochoa C.
Montoro Pereira D.
Nogal Ruiz JJ.
Fernández Portillo C.
Muelas Serrano S.
Gómez Barrio A.
Bahsas A.
Amaro-Luis J.
Arch.
Pharm. (Weinheim, Ger.)
2005,
338:
32
21c Kouznetsov VV.
Zubkov FI.
Mora U.
Nikitina EV.
Synthesis
2007,
375
22 Full crystallographic data for indenoquinoline 7c will
be published elsewhere.
23 Another commonly used oxidant, DDQ
in MeCN, was less efficient for this process due poor solubility
of the starting tetrahydroindeno[2,1-c ]quinolines.
24 Antitumoral and cytotoxic activities
for this new series of compounds will be published in due course.
